Short Interest in Demant A/S Unsponsored ADR (OTCMKTS:WILYY) Declines By 52.2%

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) was the recipient of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totaling 970 shares, a decrease of 52.2% from the May 31st total of 2,028 shares. Based on an average daily volume of 354 shares, the short-interest ratio is presently 2.7 days. Currently, 0.0% of the company’s stock are sold short.

Demant A/S Price Performance

OTCMKTS:WILYY opened at $20.66 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65. The firm’s fifty day moving average is $18.54 and its 200-day moving average is $16.51. Demant A/S has a 52 week low of $13.45 and a 52 week high of $20.98.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on WILYY. Zacks Research upgraded shares of Demant A/S to a “hold” rating in a research note on Friday, June 26th. Morgan Stanley raised Demant A/S from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, June 23rd. Finally, Jefferies Financial Group raised Demant A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy”.

About Demant A/S

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.